Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Free Cash Flow (2016 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Free Cash Flow for 15 consecutive years, with $386.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow rose 88.59% year-over-year to $386.8 million, compared with a TTM value of $780.5 million through Dec 2025, up 40.08%, and an annual FY2025 reading of $780.5 million, up 40.08% over the prior year.
  • Free Cash Flow was $386.8 million for Q4 2025 at Neurocrine Biosciences, up from $228.8 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $386.8 million in Q4 2025 and bottomed at -$125.8 million in Q1 2023.
  • Average Free Cash Flow over 4 years is $139.4 million, with a median of $121.9 million recorded in 2023.
  • Peak annual rise in Free Cash Flow hit 194.67% in 2024, while the deepest fall reached 59.59% in 2024.
  • Year by year, Free Cash Flow stood at $87.2 million in 2021, then soared by 39.79% to $121.9 million in 2023, then soared by 68.25% to $205.1 million in 2024, then soared by 88.59% to $386.8 million in 2025.
  • Business Quant data shows Free Cash Flow for NBIX at $386.8 million in Q4 2025, $228.8 million in Q3 2025, and $102.8 million in Q2 2025.